Letters to the Editors
Response to ‘Considering the chemopreventive potential of nicotinamide in Gilmore's Bayesian analysis’
First published: 06 July 2018
No abstract is available for this article.
References
- 1Patrick S. Phelan. Chemopreventive potential of nicotinamide in Gilmore’s Bayesian analysis. Aust. J. Dermatol. 2018; 10.1111/ajd.12849.
- 2Gilmore SJ. Nicotinamide and skin cancer chemoprevention: the jury is still out. Aust. J. Dermatol. 2018; 59: 6–9.
- 3Marsman M, Wagenmakers E-J. Three insights from a Bayesian interpretation of the one-sided P value. Educ. Psychol. Meas. 2017; 77: 1–11.
- 4Morey RD, Hoekstra R, Rouder JN et al. The fallacy of placing confidence in confidence intervals. Psychon. Bull. Rev. 2016; 23: 103–23.
- 5Chen AC, Martin AJ, Choy B et al. A phase 3 trial of nicotinamide for skin-cancer chemoprevention. N. Engl. J. Med. 2015; 373: 1618–26.
